XHKG
1609
Oct 28, Last price
54.45
1D
2.35%
1Q
-51.81%
Jan 2017
11,243.75%
IPO
7,907.35%
Name
Chong Kin Group Holdings Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carbon fiber reinforced PEEK suture anchor; interference screws and sheath fixation system, bioabsorbable interference screw, bioabsorbable interference screws and sheath fixation system, PEEK screws and sheath fixation system, and PEEK composite interference screw; suture buttons and high-strength sutures, such as adjustable suture button, fixed suture button, ultra-high molecular weight polyethylene(UHMWPE) suture; meniscus repair systems, all-suture meniscus repair system, accurFix all-inside meniscus repair system, and multi-needle and flexible meniscus repair system. The surgical equipment and associated medical consumables, includes plasma RF ablation equipment, arthroscopic surgical shaver, arthroscopic camera system, and disposable shaver blade plasma electrode. Its other products includes disposable PRP preparation kit, desktop centrifuge. The company also provides biomaterial platform, imaging and dynamic platform, intelligent medicine platform, and tissue engineering platform. The company was founded in 2017 and is headquartered in Beijing, China.
Key people
Wai Kwong Chau
Assistant General Manager - Projects · since 2015
Jack Yeung
Assistant General Manager - Administration · since 2015
Pik So Yu
Financial Controller · since 2018
Man Tim Cheung
Chief Executive Officer, Executive Director · since 2016
Chi Chung Fung
Executive Director · since 2016
Biao Ni
Executive Director · since 2018
Rui Yang
Executive Director · since 2019
Company Secretary · since 2018
Chairman of the Board, Chief Executive Officer · since 2018
Yifei Li
Non-Executive Independent Director · since 2018
Ping Kuen Tam
Non-Executive Independent Director · since 2018
Non-Executive Independent Director · since 2018
Valuation
Title HKD in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |